GC Biopharma USA

GC Biopharma USA is the North American subsidiary of GC Biopharma, a prominent South Korean biopharmaceutical company specializing in plasma-derived therapies and vaccines. The company focuses on the commercialization and clinical development of biologics for rare diseases and immunological disorders. Its flagship product, ALYGLO (immune globulin intravenous, human-stng), received FDA approval in late 2023 for the treatment of primary humoral immunodeficiency in adults. Based in Teaneck, New Jersey, GC Biopharma USA serves as a strategic hub for bringing the parent company's global portfolio to the United States market. The organization is dedicated to improving patient outcomes through innovative protein therapies and a robust supply chain of plasma-derived medicines.